Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitro

Fig. 1

TF mRNA reduction after Dabrafenib and Trametinib treatment. RT-PCR quantification of A375 (a) and SK-MEL-28 (b) cells treated with Trametinib/Dabrafenib for 48 h. Data are expressed as the mean ± standard deviation. Experiments were performed as technical triplicates over biological triplicates, with a total of 9 data points. Data were presented as mean ± SD and differences were considered statistically significant when p < 0.05

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us